AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15705641
Drug: Linezolid 600
RxNorm normalized name: linezolid 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid 600 mg every 12 h
Trial: 14998986
Drug: Quinupristin-dalfopristin 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinupristin-dalfopristin 7.5 mg/kg every 8 h
Trial: 9455715
Drug: Carbopol matrix
RxNorm normalized name: Carbopol 981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbopol matrix tablet with normal diet
Trial: 9455715
Drug: Carbopol matrix
RxNorm normalized name: Carbopol 981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbopol matrix tablet with high fat diet
Trial: 9455715
Drug: Carbopol matrix
RxNorm normalized name: Carbopol 981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbopol matrix tablet with high fat/high protein diet
Trial: 9455715
Drug: Lipid matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid matrix tablet with fasting condition
Trial: 9455715
Drug: Lipid matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid matrix tablet with normal diet
Trial: 9455715
Drug: Lipid matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid matrix tablet with high fat diet
Trial: 9455715
Drug: Lipid matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid matrix tablet with high fat/high protein diet
Trial: 30590573
Drug: Paracetamol (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (1000 mg) taken 1 hour prior to pain rating
Trial: 27341326
Drug: BalanceWear Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BalanceWear Therapy (BWT), weighted orthotic (WG), worn for 4 hours per day for 5 days
Trial: 27341326
Drug: Sham BalanceWear
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham BalanceWear Therapy (SWG), sham-weighted orthotic, worn for 4 hours per day for 5 days
Trial: 25622201
Drug: self-help cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self-help cognitive-behavioral therapy (shCBT) + sibutramine
Trial: 25622201
Drug: self-help cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self-help cognitive-behavioral therapy (shCBT) + placebo
Trial: 14653129
Drug: recombinant growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant growth hormone (rhGH) therapy (4 U per day for 7 days)
Trial: 14653129
Drug: human albumin
RxNorm normalized name: Human albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: human albumin (10 g every other day for 3 times)
Trial: 9124393
Drug: L-NMMA (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (3 mg/kg bolus infusion over 5 min, followed by 50 µg x kg(‐1) x min(‐1) over 120 min)
Trial: 9124393
Drug: L-arginine (17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (17 mg x kg(‐1) x min(‐1) over 30 min)
Trial: 8310886
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg post-evening meal (pem)
Trial: 30477864
Drug: Crocetin 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crocetin 7.5 mg/day
Trial: 26653113
Drug: NK3 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK3 receptor antagonist ESN364 (3-180 mg single dose)
Trial: 26653113
Drug: NK3 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK3 receptor antagonist ESN364 (20, 60, or 180 mg daily for 10 days)
Trial: 26653113
Drug: NK3 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK3 receptor antagonist ESN364 (20, 60, or 180 mg daily for 21 days)
Trial: 25516360
Drug: Donepezil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (10 mg/d for 3 months) with psychosocial intervention
Trial: 16382306
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (Lantus) subcutaneously at a dosage equal to the average of insulin/day administered in the preceding days of AN
Trial: 12593425
Drug: Tc‐99m MAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tc‐99m MAA injection in cirrhosis patients
Trial: 9650539
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine patch delivering 11 mg/day
Trial: 9650539
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine patch delivering 22 mg/day
Trial: 9650539
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine patch delivering 44 mg/day
Trial: 8589208
Drug: Argatroban (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban (2.5 mg/h for the first 48 hours, then 10 mg infused over 3 hours twice a day on days 3-7)
Trial: 2572899
Drug: Daily treatment
RxNorm normalized name: BENZOYL PEROXIDE 2.5 g in 100 g TOPICAL GEL [Acne defense Daily Treatment Serum Merle Norman]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily treatment with isoniazid (400 mg) and rifampicin (600 mg)
Trial: 2572899
Drug: Twice-weekly treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly treatment with isoniazid (900 mg) and rifampicin (600 mg)
Trial: 19508250
Drug: SRP&DOXY (scaling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP&DOXY (scaling and root planing with 14% doxycycline gel applied subgingivally)
Trial: 7830728
Drug: Lovastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (40 mg twice daily)
Trial: 8185726
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (600 mg daily)
Trial: 21910937
Drug: Daily rTMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily rTMS (5 days/week for 4 weeks, 20 treatments in total)
Trial: 21910937
Drug: Spaced rTMS
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spaced rTMS (3 days/week for 6 weeks, 18 treatments in total)
Trial: 21910937
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Daily and Spaced rTMS)
Trial: 12468134
Drug: Estradot transdermal
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradot transdermal oestrogen patch (50 microg/day)
Trial: 12468134
Drug: Menorest transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menorest transdermal oestrogen patch (50 microg/day)
Trial: 10479159
Drug: WR 238605
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WR 238605 (Tafenoquine) 300 mg daily for 7 days (Group A)
Trial: 10479159
Drug: WR 238605
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WR 238605 (Tafenoquine) 500 mg daily for 3 days (Group B)
Trial: 10479159
Drug: WR 238605
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WR 238605 (Tafenoquine) 1 dose of 500 mg (Group C)
Trial: 1720759
Drug: Alternating weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Alternating weekly chemotherapy regimen including Doxorubicin, vincristine, cyclophosphamide, bleomycin, intrathecal methotrexate and cytarabine, Methotrexate with leucovorin rescue, Ifosfamide with mesna, etoposide, and intrathecal methotrexate and cytarabine
Trial: 1720759
Drug: One additional
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One additional cycle or three monthly CHOP (consolidation treatment)
Trial: 6819029
Drug: Protein energy
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein energy supplement (energy and vitamins with 5-10% of energy from milk protein)
Trial: 6819029
Drug: Vitamins only
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamins only (a multivitamin sachet daily containing vitamins A, B, C, and D)
Trial: 26931763
Drug: On-site urine
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-site urine drug screening tests (OS-UDS) with training for GPs and supply of tests at medical offices.
Trial: 26931763
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (standard medical strategy for assessing drug use).
Trial: 20563294
Drug: Aggressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive treatment targets for LDL-C ≤70 mg/dL and systolic BP ≤115 mmHg
Trial: 20563294
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment targets for LDL-C ≤100 mg/dL and systolic BP ≤130 mmHg
Trial: 12102278
Drug: Weekly dose
RxNorm normalized name: XPOVIO 60 MG Weekly Dose Carton Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly dose of 100 mg of leflunomide
Trial: 12102278
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose of leflunomide
Trial: 9695721
Drug: Basiliximab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basiliximab (40 mg total intravenous dose) in addition to baseline dual immunosuppression (cyclosporine and steroids)
Trial: 2673516
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of semisynthetic human insulin (Novolin) providing a 70:30 ratio of NPH to regular insulin
Trial: 2673516
Drug: Variable ratio
RxNorm normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variable ratio of semisynthetic human insulin, regular and NPH (control group)
Trial: 1151293
Drug: nurse‐proctocol treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nurse‐proctocol treatment plan
Trial: 1151293
Drug: physician treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: physician treatment plan
Trial: 30395904
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg once daily during and up to 3 months after RT
Trial: 25724455
Drug: Infliximab dosing
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab dosing based on therapeutic drug monitoring (TCs)
Trial: 25724455
Drug: Infliximab dosing
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab dosing based on clinical features
Trial: 25724455
Drug: Dose escalation
RxNorm normalized name: PALFORZIA Initial Dose Escalation KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation to reach TCs of 3-7 μg/mL
Trial: 25724455
Drug: Dose reduction
RxNorm normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reduction for TCs >7 μg/mL
Trial: 24382088
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity treatment
Trial: 24382088
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity treatment
Trial: 21992849
Drug: Low-dose human
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose human atrial natriuretic peptide
Trial: 7783109
Drug: Enalapril (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10-40 mg once daily)
Trial: 2083405
Drug: Allergen-antibody complexes
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen-antibody complexes
Trial: 23869828
Drug: Pre-heated infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-heated infusion solutions (colloids and crystalloids)
Trial: 21803933
Drug: tDCS combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tDCS combined with constraint-induced movement therapy (CIMT)
Trial: 19699854
Drug: SCH 530348
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH 530348 2.5 mg daily
Trial: 10516738
Drug: Irbesartan/HCTZ combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan/HCTZ combination therapy (starting with irbesartan 75 mg/HCTZ 12.5 mg once daily, titrated to irbesartan 150 mg/HCTZ 12.5 mg, then to irbesartan 300 mg/HCTZ 25 mg if necessary)
Trial: 2371577
Drug: N-acetyl-beta-glucosaminidase (NAG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-beta-glucosaminidase (NAG) excretion measurement in patients with upper urinary tract infections
Trial: 2371577
Drug: N-acetyl-beta-glucosaminidase (NAG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-beta-glucosaminidase (NAG) excretion measurement in patients with lower urinary tract infections
Trial: 2371577
Drug: N-acetyl-beta-glucosaminidase (NAG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-beta-glucosaminidase (NAG) excretion measurement in patients with lower urinary tract symptoms and underlying diseases
Trial: 7247360
Drug: Trimethoprim (TMP)
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimethoprim (TMP) 200 mg twice daily
Trial: 7247360
Drug: Sulfamethoxazole-trimethoprim (SMX-TMP)
RxNorm normalized name: sulfamethoxazole / trimethoprim
DrugBank: Sulfamethoxazole (DB01015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfamethoxazole-trimethoprim (SMX-TMP) 800/160 mg twice daily
Trial: 28744102
Drug: Generic alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic alendronate sodium tablets (70 mg)
Trial: 28744102
Drug: Fosamax® tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosamax® tablets (70 mg) - first dose
Trial: 28744102
Drug: Fosamax® tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosamax® tablets (70 mg) - second dose
Trial: 25083010
Drug: Professionally administered
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professionally administered CBT‐I (PCBT‐I; n = 81)
Trial: 25083010
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (CTL; n = 81)
Trial: 17356993
Drug: Buprenorphine/naloxone with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone with 20 minutes counseling and weekly visits
Trial: 17356993
Drug: Buprenorphine/naloxone with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone with 45 minutes counseling and thrice weekly visits
Trial: 17356993
Drug: Medication and
RxNorm normalized name: CVS Health Medication and Topical Refill Pouch KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication and ancillary services
Trial: 10429837
Drug: Zanamivir 10
RxNorm normalized name: Zanamivir 10 mg/mL solution for infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanamivir 10 mg from the Diskhaler
Trial: 10429837
Drug: Zanamivir 10
RxNorm normalized name: Zanamivir 10 mg/mL solution for infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanamivir 10 mg from the prototype device
Trial: 10429837
Drug: Overall inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall inhalation of zanamivir
Trial: 7591715
Drug: Intravenous betahistine
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous betahistine (57, 114, and 285 micrograms i.d.)
Trial: 7591715
Drug: Oral betahistine
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral betahistine plus cetirizine and cimetidine
Trial: 7591715
Drug: Oral betahistine
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral betahistine alone
Trial: 2124446
Drug: Antihypertensive drug
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drug for a mean period of 6 weeks (range: 3‐12 weeks)
Trial: 29173856
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fixed retainers and Essix
Trial: 23990233
Drug: Adenosine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (2 mg + 2 mg) administered during PCI
Trial: 22250038
Drug: Formoterol (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol (24 µg)
Trial: 22250038
Drug: Tiotropium (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (18 µg)
Trial: 19583040
Drug: Stannous fluoride
RxNorm normalized name: Stannous Fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stannous fluoride solution (8%)
Trial: 17325272
Drug: Lipid-lowering agents
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering agents (LLA)
Trial: 17325272
Drug: Lipid-lowering agents
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering agents (LLA) indicated
Trial: 16960636
Drug: Infrared therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infrared therapy (IR therapy)
Trial: 14691360
Drug: Individual cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual cognitive‐behavioral family‐based therapy (CBFT)
Trial: 14691360
Drug: Group cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive‐behavioral family‐based therapy (CBFT)
Trial: 11054434
Drug: Renal function-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal function-based dosing
Trial: 11054434
Drug: Surface area-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surface area-based dosing
Trial: 8972014
Drug: Clopidogrel at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel at doses of 10, 25, 50, 75 or 100 mg OD
Trial: 8972014
Drug: Ticlopidine 250
RxNorm normalized name: ticlopidine 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine 250 mg BID
Trial: 1738517
Drug: Hydrogel pessary
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogel pessary containing 10 mg of prostaglandin E2
Trial: 6824553
Drug: mianserin 30
RxNorm normalized name: mianserin 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mianserin 30 mg at night
Trial: 28929669
Drug: Modified Chaiping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Chaiping decoction (6 doses per week, one dose every day in two times by oral administration)
Trial: 25081808
Drug: Daily weight
RxNorm normalized name: Thrifty White One Daily Weight Control Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily weight tracking for 6 months
Trial: 25081808
Drug: Weekly weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly weight tracking for 6 months
Trial: 22539020
Drug: Sibutramine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine (15 mg daily for 12 weeks)
Trial: 14747389
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg folic acid
Trial: 14747389
Drug: High-dose folic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose folic acid (all groups combined)
Trial: 11259518
Drug: Coping skills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coping skills intervention (daily practice with audiotaped instructions)
Trial: 9676351
Drug: Bronchoretard Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchoretard Capsules
Trial: 9676351
Drug: Capsule formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule formulation from the US market
Trial: 7990375
Drug: Veroshpiron (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veroshpiron (50-100 mg/day)
Trial: 18250489
Drug: Taliton (carvedilol)
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taliton (carvedilol) starting dose 3.125 mg twice daily, increased to target dose 25 mg twice daily over 6 months
Trial: 15564697
Drug: Bepridil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepridil (200 mg/day)
Trial: 15564697
Drug: Bepridil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepridil (200 mg/day) + Aprindine (40 or 60 mg/day)
Trial: 10365144
Drug: Chemo-immunotherapy including
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo-immunotherapy including interferon-alpha 2a, interleukin-2, 5-fluorouracil (5-FU), isotretinoin (ISO), and vinblastin (VBL)
Trial: 1967561
Drug: Xamoterol 200
RxNorm normalized name: xamoterol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xamoterol 200 mg b.i.d. for 3 months
Trial: 1967561
Drug: Digoxin 0.125
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin 0.125 mg b.i.d.
Trial: 29343201
Drug: Blackcurrant juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blackcurrant juice (500 mg of polyphenols)
Trial: 28825235
Drug: Ethyl chloride
RxNorm normalized name: Ethyl Chloride
DrugBank: Ethyl chloride (DB13259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethyl chloride aerosol spray (n=66)